YIL counteracts ghrelin-inhibited insulin release in pancreatic islets of langerhans

Abstract

Ghrelin is a peptide hormone that is produced mainly from the stomach. Ghrelin is reported to have many biological functions, such as modulating feeding behavior, energy balance, and glucose homeostasis. This study aimed to examine whether YIL, a ghrelin receptor antagonist, could counteract the effect of ghrelin-inhibited insulin release in the pancreatic islet of Langerhans. This study is experimental research using wild-type C57BL/6J mice [8-10 weeks old]. Islet of Langerhans was isolated by collagenase digestion and the insulin release [ng/islet/h] from the islet is examined by the ELISA method. Data represent means ± SEM and is analyzed by one-way ANOVA. The result showed that 8.3 mM glucose concentration increase insulin release compared to 2.8 mM glucose, respectively [0,393 ± 0,025 vs 0,219 ± 0,022 ng/islet/h]. In the presence of 8.3 mM glucose, ghrelin 1 nM showed a decrease in insulin release significantly compared to 8.3 mM glucose only [0,283 ± 0,001 vs 0,393 ± 0,025, p < 0,01]. In contrast, in the presence of 8.3 mM glucose and ghrelin 1 nM, YIL 1 μM induced insulin secretion [0,386 ± 0,012 vs 0,283 ± 0,001, p < 0,01]. In conclusion, YIL is significantly counteracted ghrelin-inhibited insulin release in pancreatic islets of Langerhans. Furthermore, YIL is one of the candidates for the treatment of type 2 diabetes.